I
Invectys
Biotech & Life Sciences · Paris, France · Founded 2010
Developing innovative approaches to immunotherapy to treat cancer MoreLess
Invectys is a biopharmaceutical company founded in 2010 by Pierre Langlade Demoyen and Simon Wain-Hobson, focused on the development of immunotherapy approaches for cancer treatment.
Pierre Langlade Demoyen, who serves as the CEO, has a background in immunology and has been involved in the development of therapeutic vaccines. Simon Wain-Hobson is a virologist and a member of the French Academy of Sciences, bringing extensive research experience to the company. Their combined expertise in immunology and virology forms the foundation of Invectys' scientific approach.
The company's core technology revolves around telomerase, an enzyme that is overexpressed in most cancer cells. Invectys is developing therapeutic vaccines that stimulate the immune system to recognize and attack cancer cells that express telomerase. This approach aims to provide a broadly applicable treatment for various types of cancer.
Invectys has developed a platform of products, including DNA-based vaccines, which are designed to trigger a cellular immune response against tumors. The company is advancing its product candidates through clinical trials to evaluate their safety and efficacy in cancer patients.
The business operates in the oncology market, a segment of the healthcare industry with a high demand for new treatment options. Invectys' business model is centered on the research and development of its proprietary technology, with the goal of commercializing its therapeutic vaccines through partnerships with larger pharmaceutical companies or by bringing them to market independently. The company has secured funding from private investors to support its research and clinical development activities.
Keywords: immunotherapy, oncology, cancer treatment, therapeutic vaccines, telomerase, clinical trials, biopharmaceutical, DNA vaccines, healthcare, immunology
Company overview
Invectys company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2010
- Headquarters
- Paris, France
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 63.2
Valuation & funding
Invectys funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Oct 2024 | $4M | — | Undisclosed | ↗ |
| GRANTOther financing | May 2020 | $14M | — | Undisclosed | — |
| EARLY VCOther financing | Oct 2018 | $17M | $66M | Undisclosed | — |
| EARLY VCOther financing | Jul 2017 | $4.4M | $18M | Undisclosed | ↗ |
| SERIES AOther financing | Jan 2016 | $7.7M | $31M | Undisclosed | — |
| EARLY VCOther financing | Mar 2015 | Undisclosed | — | ||
| SEEDOther financing | Jun 2014 | Undisclosed | — | ||
| SPINOUTOther financing | Jan 2010 | Institut Pasteur | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1.4M | 0% | −$4.3M | -302.1% |
| 2025 | $1.4M | 0% | −$4.3M | -302.1% |
| 2024 | $1.4M | 0% | −$4.3M | -302.1% |
| 2023 | $1.4M | 0% | −$4.3M | -302.1% |
| 2022 | $1.4M | -46.3% | −$4.3M | -302.1% |
| 2021 | $2.6M | +277.1% | −$1.9M | -72.4% |
| 2020 | $696K | — | −$6.5M | -937.3% |
Growth signals
Invectys website traffic
Latest recorded traffic for Invectys is 1.1K monthly website visits, down 64.5% over the last three months. Invectys's team declined 36.8% over the past year.
Comparisons
Invectys compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Invectys's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Invectys's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Invectys has talent and traffic
team presence
In the news
Latest news about Invectys
Recent press, funding announcements, and product moves mentioning Invectys — open to read from the original sources.
Market sentiment
What the market is saying about Invectys
An AI-synthesized read of the highest-engagement posts about Invectys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Invectys’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.